Evaluating a Low-Cost Therapeutic Device in Managing Head and Neck Cancer Patients With Radiation-Related Trismus
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Jan 3, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new, low-cost device designed to help patients with head and neck cancer who have difficulty opening their mouths due to radiation treatment. This condition, called trismus, can make it hard to eat, speak, and maintain good oral hygiene, which can affect overall health. The device is similar to a mouthpiece used for stretching the jaw, but it includes special sensors that measure how much pressure is being applied and how far the mouth can open. This information can help doctors tailor the treatment to each patient’s needs and encourage them to keep up with their exercises.
To join the trial, participants must be 18 years or older and have a diagnosis of radiation-induced trismus, which means they have trouble opening their mouths due to previous radiation therapy for head and neck cancer. They will need to provide written consent and be able to follow the study's requirements. This trial is currently recruiting participants, and it aims to improve the quality of life for those suffering from this condition by providing better management options.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female \>= 18 years of age at visit 1.
- • Documentation of a radiation-induced trismus diagnosis as evidenced by one or more clinical features consistent with the trismus phenotype (maximum interincisal opening (MIO) \< 35 mm) and a history of head and neck radiation
- • Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
- Exclusion Criteria:
- • Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.
- • Minors (age \< 18 years) or patients with inability to provide informed consent.
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Andrea Park, MD
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials